Kameda Arabia

kamedaarabia.com

Kameda Arabia (KA) is a Joint Venture between Dr. Soliman Fakeeh Holding company, Jeddah and Kameda Infologics Pvt Ltd based in Japan, India and local support offices in USA, UK, UAE and Malaysia. Dr. Soliman Fakeeh is a renowned name in the Saudi Arabia Healthcare Market from past three decade. Having its Business in Healthcare, Education, Medical Item Supply's and Wellness. Kameda Infologics Pvt Ltd (KI) is a provider of integrated IT solutions to the healthcare industry and has strived to develop world-class software products specializing in Healthcare. Dr. Toshitada Kameda, founder of Kameda Informatics Ltd. is a pioneer in the development of paperless solutions and is currently rendering its service to more than 200 hospitals in Japan. It was Dr. Kameda’s vision which made Kameda Medical Center a 1000 bedded super specialty hospital, south of Tokyo, into a paperless and filmless facility since 1994. KI is using the best practices, systems and quality procedures for its software development. The software development team works with the objective of providing significant value for the investment made by the customer. YASASII® is KI’s flagship Hospital Information Software (HIS) product. It is Meaningful Use 1 and 2 certified by Drummonds / CCHIT in USA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PRECISION VIROLOGICS AND BHARAT BIOTECH JOINTLY OBTAIN RIGHTS TO INTRANASAL COVID-19 VACCINE TECHNOLOGY

Precision Virologics | September 23, 2020

news image

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...

Read More

MedTech, Industrial Impact

BIONTECH TO ACQUIRE INSTADEEP FOR AI-POWERED DRUG DISCOVERY AND DEVELOPMENT

BioNTech and InstaDeep | January 12, 2023

news image

BioNTech and InstaDeep Ltd. recently signed an agreement wherein the former is set to acquire InstaDeep, a worldwide leader in AI and ML technologies. The acquisition involves a total upfront payment of about £362 million in cash, while BioNTech shares will be used to buy the remaining 100% of InstaDeep shares, excluding those currently held by BioNTech. The acquisition strengthens BioNTech's aim to establish world-leading abilities in AI-driven drug discove...

Read More

Industrial Impact, Medical

HITGEN ANNOUNCES RESEARCH AGREEMENT WITH NITRASE THERAPEUTICS FOCUSED ON DNA-ENCODED LIBRARY BASED DRUG DISCOVERY

HitGen Inc. | December 12, 2022

news image

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases. Nitrases have been implicated in numerous devastating diseases, including Parkinson's, cancer, respiratory diseases, fibrosis ...

Read More

MedTech

STEVANATO GROUP LAUNCHES EZ-FILL® KIT AND LABORATORY FILL AND FINISH SERVICE TO SUPPORT SMALL BATCH DRUG DEVELOPMENT AND COMMERCIALIZATION

Stevanato Group | January 25, 2024

news image

Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, unveiled today two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill® Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC). In a context where reducing time-to-market is key, Stevanato Group’s new EZ-fill® Kit offers fast access to ...

Read More
news image

PRECISION VIROLOGICS AND BHARAT BIOTECH JOINTLY OBTAIN RIGHTS TO INTRANASAL COVID-19 VACCINE TECHNOLOGY

Precision Virologics | September 23, 2020

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...

Read More
news image

MedTech, Industrial Impact

BIONTECH TO ACQUIRE INSTADEEP FOR AI-POWERED DRUG DISCOVERY AND DEVELOPMENT

BioNTech and InstaDeep | January 12, 2023

BioNTech and InstaDeep Ltd. recently signed an agreement wherein the former is set to acquire InstaDeep, a worldwide leader in AI and ML technologies. The acquisition involves a total upfront payment of about £362 million in cash, while BioNTech shares will be used to buy the remaining 100% of InstaDeep shares, excluding those currently held by BioNTech. The acquisition strengthens BioNTech's aim to establish world-leading abilities in AI-driven drug discove...

Read More
news image

Industrial Impact, Medical

HITGEN ANNOUNCES RESEARCH AGREEMENT WITH NITRASE THERAPEUTICS FOCUSED ON DNA-ENCODED LIBRARY BASED DRUG DISCOVERY

HitGen Inc. | December 12, 2022

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases. Nitrases have been implicated in numerous devastating diseases, including Parkinson's, cancer, respiratory diseases, fibrosis ...

Read More
news image

MedTech

STEVANATO GROUP LAUNCHES EZ-FILL® KIT AND LABORATORY FILL AND FINISH SERVICE TO SUPPORT SMALL BATCH DRUG DEVELOPMENT AND COMMERCIALIZATION

Stevanato Group | January 25, 2024

Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, unveiled today two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill® Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC). In a context where reducing time-to-market is key, Stevanato Group’s new EZ-fill® Kit offers fast access to ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us